ClinicalTrials.gg

Program

exaluren

Also written as “ELX-02” and “Exaluren”.

Its studies are mostly in Genetic Diseases, Inborn · Nephritis, Hereditary · Cystic Fibrosis · Renal Insufficiency · Cystinosis, led by Eloxx Pharmaceuticals.

Furthest: phase 2, since Aug 16, 20199 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eloxx Pharmaceuticals91 open or runningphase 2since Aug 16, 2019Jun 10, 2016Jun 30, 2027phase 2 · NCT07523581

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2016First study: phase 1 study in Genetic Diseases, InbornFirst studyNCT02807961 · 42 enrolled
  2. Aug 30, 2017Phase 1 study in Genetic Diseases, InbornNCT03292302 · 18 enrolled · Belgium
  3. Oct 10, 2017Phase 1 study in Genetic Diseases, InbornNCT03309605 · 62 enrolled · Belgium
  4. Dec 4, 2018Phase 1 study in Renal InsufficiencyNCT03776539 · 24 enrolled · United States
  5. Aug 16, 20193 phase 2 studiesNCT04135495, NCT04126473, NCT04069260
  6. Jun 29, 2022Phase 2 study in Nephritis, HereditaryNCT05448755 · 3 enrolled · Australia, United Kingdom
  7. Apr 5, 2026Phase 2 study in Nephritis, HereditaryNCT07523581 · 24 planned · United States, United Kingdom

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Nephritis, HereditaryNCT07523581

TargetBeta

“80S Ribosome modulator”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07523581Nephritis, Hereditary · United States, United Kingdom2RecruitingJun 30, 202724
NCT05448755Nephritis, Hereditary · Australia, United Kingdom2CompletedSep 11, 20233
NCT04135495Cystic Fibrosis · United States, Canada2CompletedOct 3, 202217
NCT04126473Cystic Fibrosis · Australia, Germany, Israel2CompletedApr 6, 202217
NCT04069260Genetic Diseases, Inborn · Canada2TerminatedDec 17, 20193
NCT03776539Renal Insufficiency · United States1CompletedJul 30, 201924
NCT03309605Genetic Diseases, Inborn · Belgium1CompletedJun 17, 201962
NCT03292302Genetic Diseases, Inborn · Belgium1CompletedDec 15, 201718
NCT02807961Genetic Diseases, Inborn1TerminatedFeb 201742

How it is read

Names in the registry

  • “ELX-02”, 8 entries
  • “Exaluren”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.